Teprotumumab Effectively Reduces Proptosis in Active Thyroid Eye Disease
April 26, 2019

Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease, according to phase 3 confirmatory trial data presented at the AACE 28th Annual Scientific & Clinical Congress.